Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Am Chem Soc ; 146(22): 15366-15375, 2024 Jun 05.
Article in English | MEDLINE | ID: mdl-38768956

ABSTRACT

Inspired by the specificity of α-(2,9)-sialyl epitopes in bacterial capsular polysaccharides (CPS), a doubly fluorinated disaccharide has been validated as a vaccine lead against Neisseria meningitidis serogroups C and/or B. Emulating the importance of fluorine in drug discovery, this molecular editing approach serves a multitude of purposes, which range from controlling α-selective chemical sialylation to mitigating competing elimination. Conjugation of the disialoside with two carrier proteins (CRM197 and PorA) enabled a semisynthetic vaccine to be generated; this was then investigated in six groups of six mice. The individual levels of antibodies formed were compared and classified as highly glycan-specific and protective. All glycoconjugates induced a stable and long-term IgG response and binding to the native CPS epitope was achieved. The generated antibodies were protective against MenC and/or MenB; this was validated in vitro by SBA and OPKA assays. By merging the fluorinated glycan epitope of MenC with an outer cell membrane protein of MenB, a bivalent vaccine against both serogroups was created. It is envisaged that validation of this synthetic, fluorinated disialoside bioisostere as a potent antigen will open new therapeutic avenues.


Subject(s)
Halogenation , Animals , Mice , N-Acetylneuraminic Acid/chemistry , Meningococcal Vaccines/immunology , Meningococcal Vaccines/chemistry , Neisseria meningitidis, Serogroup B/immunology , Neisseria meningitidis, Serogroup B/chemistry , Meningitis, Meningococcal/prevention & control , Meningitis, Meningococcal/immunology
2.
Angew Chem Int Ed Engl ; 61(41): e202209556, 2022 10 10.
Article in English | MEDLINE | ID: mdl-35950629

ABSTRACT

Acinetobacter baumannii is a opportunistic bacterial pathogen responsible for serious nosocomial infections that is becoming increasingly resistant against antibiotics. Capsular polysaccharides (CPS) that cover A. baumannii are a major virulence factor that play an important role in pathogenesis, are used to assign serotypes and provide the basis for vaccine development. Synthetic oligosaccharides resembling the CPS of A. baumannii 17978 were printed onto microarray slides and used to screen sera from patients infected with A. baumannii as well as a monoclonal mouse antibody (mAb C8). A synthetic oligosaccharide emerged from glycan array screening as lead for the development of a vaccine against A. baumannii 17978. Tetrasaccharide 20 is a key epitope for recognition by an antibody and is a vaccine lead.


Subject(s)
Acinetobacter Infections , Acinetobacter baumannii , Glycoconjugates , Vaccines, Synthetic , Acinetobacter Infections/prevention & control , Acinetobacter baumannii/drug effects , Animals , Anti-Bacterial Agents/pharmacology , Epitopes , Glycoconjugates/pharmacology , Humans , Mice , Oligosaccharides , Polysaccharides , Vaccines, Synthetic/pharmacology , Virulence Factors
3.
ACS Appl Bio Mater ; 5(5): 2185-2192, 2022 05 16.
Article in English | MEDLINE | ID: mdl-35435657

ABSTRACT

Nanoparticles that modulate innate immunity can act as vaccine adjuvants and antigen carriers and are promising alternatives to conventional anticancer therapy. Nanoparticles might, upon contact with serum, activate the complement system that might in turn result in clearance and allergic reactions. Herein, we report that ultrasmall glyconanoparticles decorated with nonimmunogenic α-(1-6)-oligomannans trigger an innate immune response without drastically affecting the complement system. These negatively charged glyconanoparticles (10-15 nm) are stable in water and secrete proinflammatory cytokines from macrophages via the NF-κB signaling pathway. The glyconanoparticles can be used as immunomodulators for monotherapy or in combination with drugs and vaccines.


Subject(s)
Immunity, Innate , Nanoparticles , Adjuvants, Immunologic/pharmacology , Complement System Proteins , Cytokines
4.
Vaccine ; 40(7): 1038-1046, 2022 02 11.
Article in English | MEDLINE | ID: mdl-35033388

ABSTRACT

Streptococcus pneumoniae (S. pneumoniae)infections are the leading cause of child mortality globally. Currentvaccines fail to induceaprotective immune response towards a conserved part of the pathogen,resulting in newserotypescausing disease. Therefore, new vaccinestrategies are urgently needed.Described is atwo-pronged approach combiningS. pneumoniaeproteins, pneumolysin (Ply) and pneumococcal surface protein A (PspA),with aprecisely defined synthetic oligosaccharide,wherebythe carrier protein actsas a serotype-independent antigen to provideadditional protection. Proof of concept in mice and swine modelsrevealed thatthe conjugatesinhibited colonization of the nasopharynx, decreased the bacterial load and reduced disease severity in the bacteria challenge model. Immunization of piglets provided the first evidence for the immunogenicity and protective potential of synthetic glycoconjugate vaccine in a large animal model.Acombination of synthetic oligosaccharides with proteins from the target pathogen opens the path to create broadly cross-protective ("universal") pneumococcal vaccines.


Subject(s)
Pneumococcal Infections , Streptococcus pneumoniae , Animals , Antibodies, Bacterial , Bacterial Proteins , Glycoconjugates , Mice , Pneumococcal Vaccines , Serogroup , Swine
5.
Angew Chem Int Ed Engl ; 60(26): 14679-14692, 2021 06 21.
Article in English | MEDLINE | ID: mdl-33852172

ABSTRACT

Streptococcus suis bacteria are one of the most serious health problems for pigs and an emerging zoonotic agent in humans working in the swine industry. S. suis bacteria express capsular polysaccharides (CPS) a major bacterial virulence factor that define the serotypes. Oligosaccharides resembling the CPS of S. suis serotypes 2, 3, 9, and 14 have been synthesized, glycans related to serotypes 2 and 9 were placed on glycan array surfaces to screen blood from infected pigs. Lead antigens for the development of semi-synthetic S. suis serotypes 2 and 9 glycoconjugate veterinary vaccines were identified in this way.


Subject(s)
Anti-Bacterial Agents/pharmacology , Antigens/immunology , Glycoconjugates/pharmacology , Polysaccharides, Bacterial/immunology , Streptococcus suis/drug effects , Vaccines, Synthetic/pharmacology , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/immunology , Antigens/chemistry , Drug Discovery , Glycoconjugates/chemistry , Glycoconjugates/immunology , Polysaccharides, Bacterial/chemistry , Vaccines, Synthetic/chemistry , Vaccines, Synthetic/immunology
6.
ACS Appl Mater Interfaces ; 12(39): 43380-43387, 2020 Sep 30.
Article in English | MEDLINE | ID: mdl-32875786

ABSTRACT

Malaria, a mosquito-borne disease caused by Plasmodium species, claims more than 400,000 lives globally each year. The increasing drug resistance of the parasite renders the development of new anti-malaria drugs necessary. Alternatively, better delivery systems for already marketed drugs could help to solve the resistance problem. Herein, we report glucose-based ultra-small gold nanoparticles (Glc-NCs) that bind to cysteine-rich domains of Plasmodium falciparum surface proteins. Microscopy shows that Glc-NCs bind specifically to extracellular and all intra-erythrocytic stages of P. falciparum. Glc-NCs may be used as drug delivery agents as illustrated for ciprofloxacin, a poorly soluble antibiotic with low antimalarial activity. Ciprofloxacin conjugated to Glc-NCs is more water-soluble than the free drug and is more potent. Glyco-gold nanoparticles that target cysteine-rich domains on parasites may be helpful for the prevention and treatment of malaria.


Subject(s)
Antimalarials/pharmacology , Ciprofloxacin/pharmacology , Gold/chemistry , Metal Nanoparticles/chemistry , Plasmodium falciparum/drug effects , Antimalarials/chemistry , Ciprofloxacin/chemistry , Glucose/chemistry , Molecular Structure , Parasitic Sensitivity Tests , Particle Size , Surface Properties
SELECTION OF CITATIONS
SEARCH DETAIL
...